Basic and clinical studies of biapenem in the field of urology

• Published in: CHEMOTHERAPY Vol. 42; no. Supplement4; pp. 460 - 467
• Main Authors: Saito, Isao, Saiko, Yasushi
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1994
• Subjects: Biapenem
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.42.Supplement4_460

Basic and clinical studies on biapenem (BIPM), a new carbapenem, in urological infections were performed with the following results. 1. Antibacterial activity The MICs of BIPM against 223 strains of 11 species of clinical isolates were determined, and compared with those of imipenem (IPM), ceftazidim (CAZ), piperacillin (PIPC) and ofloxacin (OFLX). BIPM was more active than the reference antibiotics against methicillin-sensitive Staphylococcus aureus (MSSA), Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii and Pseudomonas aeruginosa. BIPM was a little less active than 1PM and was as active as PIPC against Enterococcus faecalis. BIPM showed a less activity by 1 tube against Klebsiella oxytoca, when compared to CAZ, but was as active as IPM. BIPM was a little less active than OFLX against Enterobacter cloacae and Morganella morganii, but was satisfactry, showing more activity by 1-2 tube, when compared to IPM. BIPM was a little less active than CAZ and OFLX against Proteus mirabilis but was satisfactry, showing more activity by 1 tube, when compared to IPM and PIPC. Activity of the reference antibiotics including BIPM against methicillin-resistant S. aureus (MRSA) was not satisfactry. 2. The concentration of BIPM in the prostate The mean ratios of prostatic tissue concentration to serum level were 0.13 at 60-110 min after 150mg administration of BIPM, and were 0.07 at 90-105 min after 300 mg administration of BIPM. 3. Clinical study BIPM, at 600-900 mg daily in 2 divided doses for 5 days, was administered to 1 patient with acute uncomplicated pyelonephritis and 9 patients with complicated UTI to evaluate its clinical response. According to the Japanese UTI committee's criteria, the clinical efficacy was excellent in 1 for acute uncomplicated pyelonephritis, and excellent in 1, good in 3, poor in 3 for complicated UTI. Bacteriologically, all strains were eradicated. Neither side effects nor abnormal laboratry changes were observed. From above results, BIPM can be an useful antibiotics for urological infections.